CRISPR Therapeutics AG Share Price

CRISPR Therapeutics AG Share Price

NASDAQ: CRSP | Mid Cap
$51.01
-$3.26 (-6%) Last updated on 30 Oct, 2026 | 23:42 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

CRISPR Therapeutics AG Stock Performance

Open
$53.28
Prev. Close
$54.27
Circuit Range
N/A
Day Range
$51.01 - $54.02
Year Range
$44.19 - $65.89
Volume
19,756
Average Traded
$52.35

CRISPR Therapeutics AG Share Price Today

As of 30 October 2026, CRISPR Therapeutics AG's share price is $51.01. The stock opened at $53.28, compared to its previous close of $54.27. During today's trading session, CRISPR Therapeutics AG's share price traded between $51.01 and $54.02, with an average price of $52.52. Over the past 52 weeks, the stock has recorded a high of $65.89 and a low of $44.19. In terms of performance, CRISPR Therapeutics AG's share price has declined by 2.50% over the last six months and is down 20.26% on a year-on-year basis.

CRISPR Therapeutics AG Share Price Chart

Line chart of the CRISPR Therapeutics AG price trend over the selected period. The price fell overall, ranging from 51.01 to 54.02, ending at 51.01.
$51.01$54.02
L
Show Current Price
H

CRISPR Therapeutics AG Stock Fundamentals & Key Indicators

Market Cap
$4.59B
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-4.67
Revenue (TTM)
$3.51B
Return On Equity (TTM)
-25.83%
Profit Margin
-16569.80%
Debt to Equity
0.34
Quarterly Earnings Growth YoY
14.36%

CRISPR Therapeutics AG Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.89$0.86$1.46$10.18
Net Profit-$106.44-$130.61-$122.93-$91.15
Net Profit Margin-11959.55%-15187.21%-8419.86%-895.38%
Income ChangeN/A-22.71%5.88%25.85%

CRISPR Therapeutics AG Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$1.20$371.21$37.31$3.51
Net Profit-$650.18-$153.61-$366.25-$581.60
Net Profit Margin-54181.67%-41.38%-981.64%-16569.80%
Income ChangeN/A76.37%-138.43%-58.80%

About CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

CRISPR Therapeutics AG Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$55.45
$51.01
-7.99%
Sep 2026
$56.35
$55.44
-6.62%
Aug 2026
$48.23
$59.37
+23.80%
Jul 2026
$54.82
$47.95
-12.11%
Jun 2026
$54.48
$54.56
-2.83%
May 2026
$51.98
$56.15
+7.32%
Apr 2026
$48.73
$52.32
+10.10%
Mar 2026
$58.05
$47.52
-21.02%
Feb 2026
$49.25
$60.17
+20.34%
Jan 2026
$52.66
$50.00
-4.59%
Dec 2025
$51.93
$52.41
-1.99%
Nov 2025
$63.06
$53.47
-16.41%

CRSP Share Price FAQs